Title : The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.

Pub. Date : 2020 Nov

PMID : 33096322






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Asciminib is a potent, orally bioavailable, investigational drug that specifically and potently inhibits the tyrosine kinase activity of native ABL1, together with that of the chimeric BCR-ABL1 oncoprotein which causes chronic myeloid leukemia (CML). asciminib BCR activator of RhoGEF and GTPase Homo sapiens